» Articles » PMID: 38446573

Enduring Consensus Guidelines for Cervical Cancer Screening and Management: Introduction to the Scope and Process

Abstract

Objectives: The Enduring Consensus Cervical Cancer Screening and Management Guidelines (Enduring Guidelines) effort is a standing committee to continuously evaluate new technologies and approaches to cervical cancer screening, management, and surveillance.

Methods And Results: The Enduring Guidelines process will selectively incorporate new technologies and approaches with adequate supportive data to more effectively improve cancer prevention for high-risk individuals and decrease unnecessary procedures in low-risk individuals. This manuscript describes the structure, process, and methods of the Enduring Guidelines effort. Using systematic literature reviews and primary data sources, risk of precancer will be estimated and recommendations will be made based on risk estimates in the context of established risk-based clinical action thresholds. The Enduring Guidelines process will consider health equity and health disparities by assuring inclusion of diverse populations in the evidence review and risk assessment and by developing recommendations that provide a choice of well-validated strategies that can be adapted to different settings.

Conclusions: The Enduring Guidelines process will allow updating existing cervical cancer screening and management guidelines rapidly when new technologies are approved or new scientific evidence becomes available.

Citing Articles

Will methylation assays be part of a full molecular strategy to improve clinical management of cervical neoplasia?.

El-Zein M, Franco E Epigenomics. 2024; 16(18):1197-1201.

PMID: 39320908 PMC: 11485881. DOI: 10.1080/17501911.2024.2402684.


Enhancing Cervical Cancer Screening with 7-Type HPV mRNA E6/E7 Testing on Self-Collected Samples: Multicentric Insights from Mexico.

Flores C, Falang B, Gomez-Laguna L, Gutierrez G, Leon J, Uribe M Cancers (Basel). 2024; 16(13).

PMID: 39001547 PMC: 11240307. DOI: 10.3390/cancers16132485.

References
1.
Wentzensen N, Arbyn M, Berkhof J, Bower M, Canfell K, Einstein M . Eurogin 2016 Roadmap: how HPV knowledge is changing screening practice. Int J Cancer. 2016; 140(10):2192-2200. DOI: 10.1002/ijc.30579. View

2.
Bouvard V, Wentzensen N, Mackie A, Berkhof J, Brotherton J, Giorgi-Rossi P . The IARC Perspective on Cervical Cancer Screening. N Engl J Med. 2021; 385(20):1908-1918. DOI: 10.1056/NEJMsr2030640. View

3.
Egemen D, Perkins R, Clarke M, Guido R, Huh W, Saraiya M . Risk-Based Cervical Consensus Guidelines: Methods to Determine Management if Less Than 5 Years of Data Are Available. J Low Genit Tract Dis. 2022; 26(3):195-201. PMC: 9232276. DOI: 10.1097/LGT.0000000000000685. View

4.
Egemen D, Cheung L, Chen X, Demarco M, Perkins R, Kinney W . Risk Estimates Supporting the 2019 ASCCP Risk-Based Management Consensus Guidelines. J Low Genit Tract Dis. 2020; 24(2):132-143. PMC: 7147417. DOI: 10.1097/LGT.0000000000000529. View

5.
Downs Jr L, Nayar R, Gerndt J, Saslow D . Implementation in action: Collaborating on the transition to primary HPV screening for cervical cancer in the United States. CA Cancer J Clin. 2023; 73(5):458-460. DOI: 10.3322/caac.21786. View